SOFINNOVA-PARTNERS
30.6.2021 10:02:11 CEST | Business Wire | Press release
Sofinnova Partners , a leading European life sciences venture capital firm based in Paris, London and Milan, announced today three new investments from the Sofinnova Telethon Fund, its early-stage fund dedicated to investments in rare, genetic diseases. The startups, AAVantgarde Bio , Alia Therapeutics , and Borea Therapeutics , are developing promising new therapies for rare, genetic diseases.
Graziano Seghezzi, Managing Partner at Sofinnova Partners, commented: “These investments mark an important step in our mission to support the excellent scientific research coming out of Italian academic and research centers. They also highlight the exceptional flow of new investment opportunities in Italian biotech, and the important role that venture capital plays in enabling ground-breaking treatments to reach patients suffering from rare, genetic diseases who today have very few therapeutic options.”
The Sofinnova Telethon Fund is the largest fund entirely dedicated to biotechnology in Italy. The team is led by technology transfer specialists Lucia Faccio and Paola Pozzi, Partners at Sofinnova Partners, who are based in the firm’s Milan office.
The three new seed investments, totaling €6M, align with the fund’s investment strategy to seek out and support the best Italian science and the most promising entrepreneurs to develop world-class companies in the field of rare, genetic diseases.
AAVantgarde Bio, based in Milan, is developing gene therapies for inherited retinal disorders. The founder, Professor Alberto Auricchio, is a highly recognized scientist and a pioneer in the field of gene therapy. The company’s technology builds on existing AAV, or adeno-associated virus-based platforms, which are the main viral vector technology used in gene therapy applications. Existing AAV-based platforms have been limited by capacity, and AAVantgarde Bio responds to this challenge by enabling delivery of large genes to tissue and cells in vivo. The company is a spin-off of TIGEM, an international research institute based in Naples that is owned and managed by the Telethon Foundation.
Alia Therapeutics, based in Trento, is developing next generation CRISPR-based medicine for safer on-target in vivo gene editing approaches to the treatment of retinal degeneration. Alia is a spin-off of the University of Trento and was accelerated at BiovelocITA, Italy’s first biotechnology accelerator co-founded in 2015 by Sofinnova Partners and two serial entrepreneurs, Silvano Spinelli and Gabriella Camboni. It is the second company to emerge from the accelerator, following the success of Enthera Pharmaceuticals, another Italian startup that is part of Sofinnova Partners’ portfolio. This round of financing also included participation from BiovelocITA, Indaco Venture Partners, and a group of Italian investors brought together by Banor SIM and Banca Profilo.
Ms. Pozzi, Partner at Sofinnova Partners, board member of AAVantgarde Bio and an investment partner in Alia Therapeutics, commented: “We are delighted to support these innovative biotech startups as they advance promising programs towards preclinical and clinical development. Both companies have highly qualified scientific teams with globally recognized expertise in the field of gene therapy and gene editing. We are confident in the potential of these companies to tackle the limitations of existing therapies and develop treatments to diseases that do not have adequate solutions today.”
Borea Therapeutics, based in Milan, is advancing a new generation of gene therapies that would enable targeting of specific tissues and cells. The company’s innovative technology could enable viral vectors to reach areas like the central nervous system (CNS) and peripheral nervous system (PNS), thus opening the door to new therapeutic options. Borea Therapeutics was co-founded by Professor Paul Heppenstall and the European Molecular Biology Lab (EMBL), an intergovernmental research organization with six research sites throughout Europe, including one in Rome. The company’s research activities are performed in collaboration with Scuola Internazionale Superiore di Studi Avanzati (SISSA), a scientific center of excellence in Trieste.
Ms. Faccio, Partner at Sofinnova Partners and a board member of Borea Therapeutics, commented: “One of the major limitations of gene therapy is the difficulty of selectively targeting specific cells or tissues. Borea Therapeutics’ technology has the potential to pinpoint specific tissues and cells, which would enable the use of lower doses, making treatment safer and more effective for patients. This could be the next breakthrough in gene therapy.”
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply-established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management. For more information, please visit: www.sofinnovapartners.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210630005320/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 14:00:00 CET | Press release
A domain-trained AI agent workforce enables production-scale AI across regulated financial institution operations Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end
Hytera Announces 450Connect Whitelisting of PNC660 450MHz at MWC 20266.3.2026 13:02:00 CET | Press release
Hytera, a leading global provider of critical communications technologies and solutions, announced that its mission-critical smart device, the PNC660 450MHz, has been granted whitelist certification by 450Connect during the Mobile World Congress 2026 (MWC26), held from March 2 to 5 in Barcelona, Spain. This certification authorizes the device for full commercial deployment across European 450MHz private broadband networks, marking a significant milestone for Hytera in delivering reliable, secure, and robust communication solutions to energy providers and other critical infrastructure sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305205209/en/ Hytera launches the MCX Smart Device PNC660 450MHz 450Connect is the exclusive licensee and operator of the nationwide 450MHz radio network in Germany and across Europe. Its whitelist program enforces stringent evaluation criteria covering device compatibility, network inte
Andersen Consulting udvider sine kompetencer gennem samarbejde med Opinno6.3.2026 12:41:00 CET | Pressemeddelelse
Andersen Consulting styrker sin platform gennem en samarbejdsaftale med Opinno, et globalt konsulentfirma med hovedsæde i Spanien, der integrerer digital transformation med virksomhedsinnovation. Opinno blev stiftet i 2008 og hjælper organisationer med at gentænke, hvordan de innoverer, transformerer og vokser i den digitale økonomi. Firmaet anvender designtænkning, agile metoder og åbne samarbejdsmodeller til at levere resultater inden for tre kerneområder: Digital transformation, innovation samt indhold og økosystemer. Deres praksis inden for digital transformation lægger vægt på ai fra både et strategisk og et designmæssigt perspektiv, mens deres innovationspraksis accelererer udviklingen og markedsføringen af produkter og tjenester. I kraft af sine programmer for indhold og økosystemer fremmer Opinno engagement og hjælper med at opbygge sammenhængende, fremtidsparate organisationer. "Hos Opinno er innovation og digital transformation mere end blot processer; de er kanaler for mærkb
Smoke Free Sweden: Brussels Warned Against Depriving Women of Best Tool to Quit Smoking6.3.2026 10:28:00 CET | Press release
On International Women’s Day (March 8), health experts are warning EU policymakers not to jeopardise women’s health by restricting or banning nicotine pouches that have helped drive one of the world’s most dramatic declines in female smoking. The warning accompanies the release of Empowerment in a Pouch, a report showing how access to oral, tobacco-free nicotine pouches has accelerated Sweden’s progress towards smoke-free status, particularly among women. European Commission proposals under consideration in the Tobacco Products Directive could reverse this progress if applied across the EU, where more than one in five women still smokes. “Sweden’s experience shows what happens when women are given realistic alternatives to smoking,” said Professor Marewa Glover, behavioural scientist and co-author. “Remove those options and you remove momentum. The danger now is that European policy ignores success and repeats past mistakes.” The report shows that since nicotine pouches became availabl
Andersen Consulting udvider platformen med Reach Consulting5.3.2026 22:05:00 CET | Pressemeddelelse
Andersen Consulting udvider sin platform i Mellemøsten gennem en samarbejdsaftale med Reach Consulting, et digitalt transformations- og rådgivningsfirma med hovedsæde i De Forenede Arabiske Emirater. Reach Consulting hjælper organisationer med at skabe vækst, håndtere risici og navigere i komplekse forandringer gennem en omfattende portefølje af ydelser, herunder digital transformation, strategi, intern revision og M&A-rådgivning. Med en tilstedeværelse i De Forenede Arabiske Emirater, Saudi-Arabien, Oman, Qatar og Jordan betjener firmaet kunder i både den offentlige og private sektor med skræddersyede løsninger, tværfaglig ekspertise og indgående lokalkendskab. Reach Consulting kombinerer skala med agilitet for at fremme driftsresultater og innovation i arbejdsstyrken. "Transformation fungerer bedst, når lokal indsigt, tværfaglig ekspertise og praktisk udførelse spiller sammen," udtalte Suhail Shaker, administrerende direktør for Reach Consulting. "Ved at samarbejde med Andersen Consu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom